Stockreport

Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc.  (KRBP) 
PDF Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the [Read more]